Home » Reports » Broker Ratings » Hikma Pharmaceuticals Plc 12.2% Potential Upside Indicated by Citigroup
broker ratings

Hikma Pharmaceuticals Plc 12.2% Potential Upside Indicated by Citigroup

Hikma Pharmaceuticals Plc with EPIC/TICKER (LON:HIK) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ this morning by analysts at Citigroup. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. Citigroup have set their target price at 1475 GBX on its stock. This indicates the analyst now believes there is a potential upside of 12.2% from today’s opening price of 1315 GBX. Over the last 30 and 90 trading days the company share price has increased 92 points and increased 314 points respectively. The 1 year high stock price is 2000 GBX while the 52 week low for the share price is 814.2 GBX.

Hikma Pharmaceuticals Plc has a 50 day moving average of 1,107.65 GBX and the 200 Day Moving Average price is recorded at 1,133.26. There are currently 241,026,009 shares in issue with the average daily volume traded being 786,708. Market capitalisation for LON:HIK is £3,132,132,987 GBP.